Carmelo (Carl) Romano, Ph.D., is Senior Director of Retina Research at the Novartis Institute for Biomedical Research in Fort Worth (NIBR/Fort Worth, formerly Alcon Pharma Research). He has been at Alcon and led the Retina Discovery Research Program there since 2004. With the combination of Alcon and Novartis research efforts, the NIBR Ophtha Unit is the largest organization in the world devoted to ophthalmic research. Several compounds have emerged from Carl’s group and entered the clinic, including AL-8309, which is currently in Phase 2/3 for Geographic Atrophy Progression. Prior to joining Alcon, Carl had spent his entire career as an academic biomedical scientist. After earning degrees from SUNY Stony Brook (Biochemistry) and Stanford (Pharmacology), he did post-doctoral stints at Yale, Rockefeller, and University of Pennsylvania before joining the faculties of Ophthalmology and Neurobiology at Washington University School of Medicine in St. Louis in 1990.